Pcas SA
PAR:PCA
Relative Value
The Relative Value of one PCA stock under the Base Case scenario is 24.65 EUR. Compared to the current market price of 8 EUR, Pcas SA is Undervalued by 68%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PCA Competitors Multiples
Pcas SA Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
FR |
Pcas SA
PAR:PCA
|
109.9m EUR | 0.5 | 12.5 | -188.7 | -6.7 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.9B USD | 5.2 | 37 | 22.9 | 33.5 | ||
US |
Danaher Corp
NYSE:DHR
|
184.1B USD | 4.2 | 22.8 | 16.6 | 20.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
41.7B USD | 6.2 | 33.7 | 26.9 | 32.4 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.7B CHF | 5.6 | 57.7 | 19.8 | 29.1 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56.3T KRW | 15.2 | 65.6 | 34.6 | 49.8 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.3B USD | 2.8 | 30.4 | 16.6 | 25.6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
27.1B USD | 7.2 | 34.4 | 23.9 | 26.6 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 9.1 | 46.8 | 32.9 | 39.9 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.6B USD | 3.1 | 37.5 | 17 | 26.2 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.8B EUR | 6.9 | 74 | 32 | 52.4 |